Author

L. Fries

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:clinical cohort / trial· 1 Organism:non-human primate· 1

Frequent Co-Authors

G. Glenn· 3 shared A. D. Portnoff· 2 shared B. Zhou· 2 shared G. Smith· 2 shared J.-H. Tian· 2 shared L. R. Ellingsworth· 2 shared M. Guebre-Xabier· 2 shared M. J. Massare· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

G. Glenn

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses

C. Rydyznski Moderbacher, C. Kim, J. Mateus, J. Plested, M. Zhu, S. Cloney-Clark, D. Weiskopf, A. Sette, L. Fries, G. Glenn, S. Crotty

This study shows NVX-CoV2373 vaccine induces CD4+ and CD8+ T cell responses, with CD4+ T cells correlating with neutralizing antibody titers.

bioRxiv · Apr 8, 2022 · PreprintImmunology

Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and QuadrivalentSeasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant

M. J. Massare, N. Patel, B. Zhou, S. Maciejewski, R. Flores, M. Guebre-Xabier, J.-H. Tian, A. D. Portnoff, L. Fries, V. Shinde, L. R. Ellingsworth, G. Glenn, G. Smith

This paper evaluates a combination vaccine against seasonal influenza and SARS-CoV-2 in animal models, showing it induces protective immune responses and prevents viral replication and disease.

bioRxiv · May 5, 2021 · PreprintImmunology

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

J.-H. Tian, N. Patel, R. Haupt, H. Zhou, S. Weston, H. Hammond, J. Lague, A. D. Portnoff, J. Norton, M. Guebre-Xabier, B. Zhou, K. Jacobson, S. Maciejewski, R. Khatoon, M. Wisniewska, , G. Smith

This study evaluates the immunogenicity and protective efficacy of the NVX-CoV2373 SARS-CoV-2 vaccine in baboons and mice, showing strong immune responses and protection without enhanced disease.

bioRxiv · Jun 29, 2020Microbiology